View in EDS

Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve.

Saved in:
Bibliographic Details
Title: Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve.
Authors: Zhang H; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, 20878, USA. huixia.zhang1@astrazeneca.com., Tang W; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, 20878, USA., Sadow S; Biometrics, Vaccines and Immune Therapies, AstraZeneca, Wilmington, DE, USA., Baronio R; Biometrics, Vaccines and Immune Therapies, R&D, AstraZeneca, Cambridge, UK., Tullio AN; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA., Hirao L; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Dzutseva V; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA., Chen CC; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA., Kiazand A; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA., Chang LJ; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Cohen TS; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Gibbs M; Clinical Development, Vaccines and Immune Therapies, AstraZeneca, Cambridge, UK.
Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2026 May; Vol. 65 (5), pp. 747-761. Date of Electronic Publication: 2026 Mar 31.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Comparative Study
Journal Info: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41917376
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+H%22">Zhang H</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, 20878, USA. huixia.zhang1@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Tang+W%22">Tang W</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, 20878, USA.<br /><searchLink fieldCode="AU" term="%22Sadow+S%22">Sadow S</searchLink>; Biometrics, Vaccines and Immune Therapies, AstraZeneca, Wilmington, DE, USA.<br /><searchLink fieldCode="AU" term="%22Baronio+R%22">Baronio R</searchLink>; Biometrics, Vaccines and Immune Therapies, R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Tullio+AN%22">Tullio AN</searchLink>; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hirao+L%22">Hirao L</searchLink>; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Dzutseva+V%22">Dzutseva V</searchLink>; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Chen+CC%22">Chen CC</searchLink>; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kiazand+A%22">Kiazand A</searchLink>; Global Patient Safety, Vaccines and Immune Therapies, R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Chang+LJ%22">Chang LJ</searchLink>; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+TS%22">Cohen TS</searchLink>; Clinical Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Gibbs+M%22">Gibbs M</searchLink>; Clinical Development, Vaccines and Immune Therapies, AstraZeneca, Cambridge, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227606849%22">Clinical pharmacokinetics</searchLink> [Clin Pharmacokinet] 2026 May; Vol. 65 (5), pp. 747-761. <i>Date of Electronic Publication: </i>2026 Mar 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22%22"> </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>7606849 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1926 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203125963%22">03125963 </searchLink><i>NLM ISO Abbreviation: </i>Clin Pharmacokinet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41917376
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40262-026-01631-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 747
    Titles:
      – TitleFull: Pharmacokinetic Comparability Assessment of Tixagevimab and Cilgavimab Developed for COVID-19 Prevention and Treatment Using Standard Exposure Metrics and Partial Area Under the Curve.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang H
      – PersonEntity:
          Name:
            NameFull: Tang W
      – PersonEntity:
          Name:
            NameFull: Sadow S
      – PersonEntity:
          Name:
            NameFull: Baronio R
      – PersonEntity:
          Name:
            NameFull: Tullio AN
      – PersonEntity:
          Name:
            NameFull: Hirao L
      – PersonEntity:
          Name:
            NameFull: Dzutseva V
      – PersonEntity:
          Name:
            NameFull: Chen CC
      – PersonEntity:
          Name:
            NameFull: Kiazand A
      – PersonEntity:
          Name:
            NameFull: Chang LJ
      – PersonEntity:
          Name:
            NameFull: Cohen TS
      – PersonEntity:
          Name:
            NameFull: Gibbs M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1179-1926
          Numbering:
            – Type: volume
              Value: 65
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Clinical pharmacokinetics
              Type: main
ResultId 1